AtriCure, Inc.

Is AtriCure, Inc. technically bullish or bearish?

As of October 31, 2025, AtriCure, Inc. shows a mildly bullish technical trend, with mixed signals from MACD and moving averages, but has underperformed the S&P 500 with a year-to-date return of 7.17% compared to 16.30%.

As of 31 October 2025, the technical trend for AtriCure, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish, indicating mixed signals. The daily moving averages are mildly bullish, suggesting some positive momentum. However, the weekly Bollinger Bands are bearish, contrasting with the monthly Bollinger Bands which are mildly bullish. The KST shows a bullish monthly trend but is mildly bearish on the weekly timeframe. Overall, the technical stance is mildly bullish, but the strength is tempered by bearish indicators on the weekly charts.<BR><BR>In terms of performance, AtriCure has underperformed compared to the S&P 500 across multiple periods, notably with a year-to-date return of 7.17% versus the S&P 500's 16.30%, and a 1-year return of -2.27% compared to 19.89% for the benchmark.

Is AtriCure, Inc. overvalued or undervalued?

As of November 1, 2022, AtriCure, Inc. has shifted to a risky valuation grade, appearing overvalued with concerning metrics such as a Price to Book Value of 3.80, a negative ROCE of -5.50%, and a P/E ratio of -92.43, despite a strong year-to-date return of 19.96%, which still lags behind the S&P 500 over the long term.

As of 1 November 2022, AtriCure, Inc. moved from a fair to a risky valuation grade, indicating a shift towards a more negative outlook. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 3.80 and an EV to Sales ratio of 3.53, which suggest that investors are paying a premium relative to its book value and sales. Additionally, the negative ROCE of -5.50% and ROE of -5.76% further highlight the company's struggles in generating returns.<BR><BR>In comparison to its peers, AtriCure's valuation ratios are concerning; for instance, Sanmina Corp. has a P/E ratio of 39.80, while AtriCure's valuation is classified as risky with a P/E ratio of -92.43. Other peers like iRhythm Technologies and Glaukos Corp. also reflect risky valuations, but AtriCure's metrics stand out for their extreme negativity. Despite a strong YTD return of 19.96%, AtriCure has underperformed the S&P 500 over the longer term, particularly in the 3Y and 5Y periods, where it lagged significantly behind the benchmark.

How big is AtriCure, Inc.?

As of Jun 18, AtriCure, Inc. has a market capitalization of $1.61 billion, with net sales of $480.08 million and a net profit of -$38.18 million over the latest four quarters. Shareholder's funds are $460.97 million, and total assets amount to $609.33 million.

As of Jun 18, AtriCure, Inc. has a market capitalization of 1,613.86 million, classifying it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 480.08 million, while the sum of Net Profit for the same period is -38.18 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 460.97 million and Total Assets at 609.33 million.

What does AtriCure, Inc. do?

AtriCure, Inc. develops and sells devices for surgical ablation of cardiac tissue and left atrial appendage exclusion, focusing on atrial fibrillation solutions. As of March 2025, it reported net sales of $124 million and a net loss of $7 million, with a market cap of approximately $1.61 billion.

Overview:<BR>AtriCure, Inc. is an atrial fibrillation (Afib) solutions company that develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and left atrial appendage exclusion, operating in the Pharmaceuticals & Biotechnology industry with a micro-cap market.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 124 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -7 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,613.86 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.08 <BR>Return on Equity: -5.76% <BR>Price to Book: 3.55<BR><BR>Contact Details:<BR>Address: 7555 Innovation Way, MASON OH: 45040-9695 <BR>Tel: 1 513 7554100 <BR>Fax: 1 513 7554567 <BR>Website: https://www.atricure.com

Should I buy, sell or hold AtriCure, Inc.?

Who are in the management team of AtriCure, Inc.?

As of March 2022, the management team of AtriCure, Inc. includes Scott Drake (Independent Chairman), Michael Carrel (CEO), and several independent directors: Mark Collar, Daniel Florin, Regina Groves, B. Kristine Johnson, and Mark Lanning. They oversee the company's strategic direction and operations.

As of March 2022, the management team of AtriCure, Inc. includes the following individuals:<BR><BR>- Mr. Scott Drake, Independent Chairman of the Board<BR>- Mr. Michael Carrel, President, Chief Executive Officer, and Director<BR>- Mr. Mark Collar, Independent Director<BR>- Mr. Daniel Florin, Independent Director<BR>- Ms. Regina Groves, Independent Director<BR>- Ms. B. Kristine Johnson, Independent Director<BR>- Mr. Mark Lanning, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.